Pf Prism Cv Drug Patent Portfolio
Pf Prism Cv owns 11 orange book drugs protected by 76 US patents with Vfend having the least patent protection, holding only 2 patents. And Torisel with maximum patent protection, holding 14 patents. Given below is the list of Pf Prism Cv's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10869924 | PD-L1 antagonist combination treatments | 12 Jul, 2037 | Active |
| US10869924 | PD-L1 antagonist combination treatments | 12 Jan, 2037 | Active |
| US10570202 | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer | 03 Aug, 2035 | Active |
| US10570202 | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer | 03 Feb, 2035 | Active |
| US11103497 | Treatment of imatinib resistant leukemia | 28 Aug, 2034 | Active |
| US11103497 | Treatment of imatinib resistant leukemia | 28 Feb, 2034 | Active |
| US8791097 | Anti-tumor activity of CCI-779 in papillary renal cell cancer | 10 Nov, 2032 | Active |
| US8791097 | Anti-tumor activity of CCI-779 in papillary renal cell cancer | 10 May, 2032 | Active |
| US8791140 | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals | 14 Jun, 2031 | Active |
| US8791140 | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals | 14 Dec, 2030 | Active |
| US8372995 | Crystalline solid forms of tigecycline and methods of preparing same | 08 Oct, 2030 | Active |
| US8217057 | Polymorphs of a c-MET/HGFR inhibitor | 06 Nov, 2029 | Active |
| US7858643 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | 08 Oct, 2029 | Active |
| US7879828 | Tigecycline compositions and methods of preparation | 05 Feb, 2029 | Active |
| US8975242 | Tigecycline compositions and methods of preparation | 24 Oct, 2028 | Active |
| US8269040 | Derivatives of venlafaxine and methods of preparing and using the same | 05 Jul, 2027 | Active |
| US7767678 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | 23 May, 2027 | Active |
| US7825137 | Method of treating abnormal cell growth | 12 May, 2027 | Active |
| US7767678 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | 23 Nov, 2026 | Active |
| US8026276 | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant | 20 Jul, 2026 | Active |
| US7417148 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | 11 Jun, 2026 | Active |
| US7919625 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | 11 Jun, 2026 | Active |
| USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds | 08 Jun, 2026 | Active |
| US10588975 | Tigecycline compositions and methods of preparation | 13 Mar, 2026 | Active |
| US9254328 | Tigecycline compositions and methods of preparation | 13 Mar, 2026 | Active |
| US9694078 | Tigecycline compositions and methods of preparation | 13 Mar, 2026 | Active |
| US8026276 | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant | 20 Jan, 2026 | Active |
| US7417148 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | 11 Dec, 2025 | Active |
| US7919625 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | 11 Dec, 2025 | Active |
| USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds | 08 Dec, 2025 | Active |
| US6534524 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | 29 Oct, 2025 | Active |
| US7230098 | Aminoheteroaryl compounds as protein kinase inhibitors | 26 Aug, 2025 | Active |
| US6534524 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | 29 Apr, 2025 | Expired |
| US8785632 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | 01 Mar, 2025 | Expired |
| USRE42376 | Substituted 3-cyanoquinolines | 13 Oct, 2024 | Expired |
| USRE42376 | Substituted 3-cyanoquinolines | 13 Apr, 2024 | Expired |
| US6984403 | Azithromycin dosage forms with reduced side effects | 14 Feb, 2024 | Expired |
| US7887844 | Multiparticulate crystalline drug compositions having controlled release profiles | 14 Feb, 2024 | Expired |
| US8299116 | CCI-779 concentrate formulations | 25 Jan, 2024 | Expired |
| US8455539 | CCI-779 concentrate formulations | 25 Jan, 2024 | Expired |
| US8722700 | CCI-779 formulations for parenteral administration | 25 Jan, 2024 | Expired |
| US8299116 | CCI-779 concentrate formulations | 25 Jul, 2023 | Expired |
| US8455539 | CCI-779 concentrate formulations | 25 Jul, 2023 | Expired |
| US8722700 | CCI-779 formulations for parenteral administration | 25 Jul, 2023 | Expired |
| US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate | 25 Mar, 2023 | Expired |
| US7265119 | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | 03 Feb, 2023 | Expired |
| US6890927 | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | 06 Nov, 2022 | Expired |
| US7265119 | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | 03 Aug, 2022 | Expired |
| US7301023 | Chiral salt resolution | 23 May, 2022 | Expired |
| US6890927 | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | 06 May, 2022 | Expired |
| US6673838 | Succinate salt of O-desmethyl-venlafaxine | 01 Mar, 2022 | Expired |
| US6956041 | Pyrrolo[2,3-d]pyrimidine compounds | 08 Dec, 2020 | Expired |
| US7091208 | Pyrrolo[2,3-D]pyrimidine compounds | 08 Dec, 2020 | Expired |
| US7265221 | Pyrrolo[2,3-d]pyrimidine compounds | 08 Dec, 2020 | Expired |
| US7842699 | Pyrrolo[2,3-D]pyrimidine compounds | 08 Dec, 2020 | Expired |
| US6410550 | Aryl fused azapolycyclic compounds | 10 Nov, 2020 | Expired |
| US7141581 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | 30 Jun, 2020 | Expired |
| US6410550 | Aryl fused azapolycyclic compounds | 10 May, 2020 | Expired |
| USRE44768 | Rapamycin hydroxyesters | 15 Aug, 2019 | Expired |
| USRE44768 | Rapamycin hydroxyesters | 15 Feb, 2019 | Expired |
| US5989591 | Rapamycin formulations for oral administration | 11 Sep, 2018 | Expired |
| US6268489 | Azithromycin dihydrate | 31 Jul, 2018 | Expired |
| US6632803 | Pharmaceutical formulations containing voriconazole | 02 Jun, 2018 | Expired |
| US6002008 | Substituted 3-cyano quinolines | 27 Mar, 2018 | Expired |
| US5989591 | Rapamycin formulations for oral administration | 11 Mar, 2018 | Expired |
| US6068859 | Controlled-release dosage forms of Azithromycin | 30 May, 2017 | Expired |
| US5567817 | Triazole antifungal agents | 24 May, 2016 | Expired |
| USRE40183 | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines | 09 Apr, 2016 | Expired |
| US5362718 | Rapamycin hydroxyesters | 18 Oct, 2014 | Expired |
| US5362718 | Rapamycin hydroxyesters | 18 Apr, 2014 | Expired |
| US5536729 | Rapamycin formulations for oral administration | 30 Mar, 2014 | Expired |
| US5100899 | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof | 07 Jan, 2014 | Expired |
| US5536729 | Rapamycin formulations for oral administration | 30 Sep, 2013 | Expired |
| US5100899 | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof | 07 Jul, 2013 | Expired |
| USRE40086 | Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines | 25 Jun, 2013 | Expired |
| US5403833 | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof | 04 Oct, 2012 | Expired |
Latest Legal Activities on Pf Prism Cv's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Pf Prism Cv.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jul, 2024 | US8372995 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 17 Jun, 2024 | US8299116 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jun, 2024 | US10869924 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2024 | US8269040 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Dec, 2023 | US8217057 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Aug, 2023 | US10588975 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Aug, 2023 | US10570202 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jul, 2023 | US9254328 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2023 | US8026276 |
|
Expire Patent
Critical
| 02 Jan, 2023 | US7842699 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Sep, 2022 | US7919625 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Aug, 2022 | US8975242 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Jul, 2022 | US7842699 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jul, 2022 | US7879828 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jul, 2022 | US7887844 |
Pf Prism Cv's Drug Patent Litigations
Pf Prism Cv's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US6268489. The petitioner , challenged the validity of this patent, with ALLEN et al as the respondent. Click below to track the latest information on how companies are challenging Pf Prism Cv's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6890927 | June, 2021 |
Terminated-Settled
(29 Oct, 2021)
| Pfizer Inc. | Apotex Inc. et al. |
| US11103497 | August, 2019 |
Decision
(27 Oct, 2020)
| Becker Hewes | |
| US7879828 | March, 2015 |
Terminated-Denied
(16 Sep, 2015)
| Wyeth LLC | Apotex Inc. |
| US7879828 | November, 2013 |
FWD Entered
(20 Apr, 2015)
| Wyeth LLC | Apotex Inc. |
| US7879828 | August, 2014 |
Terminated-Denied
(13 Feb, 2015)
| Wyeth LLC | Initiative for Responsibility in Drug Pricing LLC |
| US6673838 | May, 2010 |
Decision
(28 May, 2010)
| Anthony F. Hadfield et al | |
| US6268489 | January, 1 |
Decision
(15 Apr, 1998)
| ALLEN et al | |
Pf Prism Cv Drug Patents' Oppositions Filed in EPO
Pf Prism Cv drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 08, 2008, by Lammert, Roland, Dr.. This opposition was filed on patent number EP02718949A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP18205542A | Jun, 2022 | König Szynka Tilmann von Renesse | Granted and Under Opposition |
| EP18205542A | May, 2022 | Pajaro Limited | Granted and Under Opposition |
| EP18205542A | May, 2022 | Pohlman, Sandra M. | Granted and Under Opposition |
| EP18205542A | May, 2022 | Boult Wade Tennant LLP | Granted and Under Opposition |
| EP18205542A | May, 2022 | Symbiosis IP Limited | Granted and Under Opposition |
| EP18205542A | May, 2022 | Hoffmann Eitle | Granted and Under Opposition |
| EP18205542A | May, 2022 | Wuesthoff & Wuesthoff Patentanwälte PartG mbB | Granted and Under Opposition |
| EP15191756A | Apr, 2022 | SANDOZ AG | Granted and Under Opposition |
| EP15703439A | Aug, 2019 | König Szynka Tilmann von Renesse | Granted and Under Opposition |
| EP15703439A | Aug, 2019 | Withers & Rogers LLP | Granted and Under Opposition |
| EP08719405A | Feb, 2018 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP12153823A | Mar, 2017 | Generics (U.K.) Limited | Revoked |
| EP12153823A | Mar, 2017 | Accord Healthcare | Revoked |
| EP08742616A | Mar, 2016 | Generics (UK) Limited | Opposition rejected |
| EP12160638A | Feb, 2015 | Generics (UK) Ltd (trading as Mylan) | Opposition rejected |
| EP06774184A | Oct, 2014 | Generics [UK] Ltd (trading as Mylan) | Patent maintained as amended |
| EP06774184A | Oct, 2014 | Fresenius Kabi Deutschland GmbH | Patent maintained as amended |
| EP06737947A | Jun, 2014 | PENTAFARMA S.A. | Patent maintained as amended |
| EP06737947A | Jun, 2014 | Hollatz, Christian | Patent maintained as amended |
| EP06737947A | Jun, 2014 | Hollatz, Christian | Patent maintained as amended |
| EP06737947A | Jun, 2014 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Patent maintained as amended |
| EP06760544A | Jan, 2014 | Taylor Wessing LLP | Revoked |
| EP06760544A | Jan, 2014 | Galenicum Health S.L. | Revoked |
| EP02781589A | Nov, 2011 | Wibbelmann, Jobst | Opposition rejected |
| EP04010248A | Mar, 2009 | Lammert, Roland, Dr. | Revoked |
| EP04010248A | Mar, 2009 | Wyeth | Revoked |
| EP04010248A | Mar, 2009 | RANBAXY PHARMACEUTICALS INC. | Revoked |
| EP03771828A | Nov, 2008 | Wichmann, Hendrik | Revoked |
| EP03771828A | Nov, 2008 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP02718949A | May, 2008 | SEPRACOR Inc | Patent maintained as amended |
| EP02718949A | May, 2008 | EGIS Gyógyszergyár Nyrt | Patent maintained as amended |
| EP02718949A | May, 2008 | Lammert, Roland, Dr. | Patent maintained as amended |
Pf Prism Cv's Family Patents
Pf Prism Cv drugs have patent protection in a total of 62 countries. It's US patent count contributes only to 14.3% of its total global patent coverage. 16 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Pf Prism Cv Drug List
Given below is the complete list of Pf Prism Cv's drugs and the patents protecting them.
1. Bosulif
Bosulif is protected by 11 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11103497
(Pediatric)
| Treatment of imatinib resistant leukemia |
28 Aug, 2034
(9 years from now)
| Active |
| US11103497 | Treatment of imatinib resistant leukemia |
28 Feb, 2034
(8 years from now)
| Active |
| US7767678
(Pediatric)
| Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
23 May, 2027
(2 years from now)
| Active |
| US7767678 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
23 Nov, 2026
(1 year, 6 months from now)
| Active |
| US7417148
(Pediatric)
| 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
11 Jun, 2026
(1 year, 1 month from now)
| Active |
| US7919625
(Pediatric)
| 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
11 Jun, 2026
(1 year, 1 month from now)
| Active |
| US7417148 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
11 Dec, 2025
(7 months from now)
| Active |
| US7919625 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
11 Dec, 2025
(7 months from now)
| Active |
| USRE42376
(Pediatric)
| Substituted 3-cyanoquinolines |
13 Oct, 2024
(6 months ago)
| Expired |
| USRE42376 | Substituted 3-cyanoquinolines |
13 Apr, 2024
(1 year, 26 days ago)
| Expired |
| US6002008 | Substituted 3-cyano quinolines |
27 Mar, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bosulif's drug page
2. Chantix
Chantix is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7265119
(Pediatric)
| Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
03 Feb, 2023
(2 years ago)
| Expired |
| US6890927
(Pediatric)
| Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
06 Nov, 2022
(2 years ago)
| Expired |
| US7265119 | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
03 Aug, 2022
(2 years ago)
| Expired |
| US6890927 | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
06 May, 2022
(3 years ago)
| Expired |
| US6410550
(Pediatric)
| Aryl fused azapolycyclic compounds |
10 Nov, 2020
(4 years ago)
| Expired |
| US6410550 | Aryl fused azapolycyclic compounds |
10 May, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Chantix's drug page
3. Inlyta
Inlyta is protected by 9 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10869924
(Pediatric)
| PD-L1 antagonist combination treatments |
12 Jul, 2037
(12 years from now)
| Active |
| US10869924 | PD-L1 antagonist combination treatments |
12 Jan, 2037
(11 years from now)
| Active |
| US10570202
(Pediatric)
| Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
03 Aug, 2035
(10 years from now)
| Active |
| US10570202 | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
03 Feb, 2035
(9 years from now)
| Active |
| US8791140
(Pediatric)
| Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
14 Jun, 2031
(6 years from now)
| Active |
| US8791140 | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
14 Dec, 2030
(5 years from now)
| Active |
| US6534524
(Pediatric)
| Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
29 Oct, 2025
(5 months from now)
| Active |
| US6534524 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
29 Apr, 2025
(10 days ago)
| Expired |
| US7141581 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
30 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inlyta's drug page
4. Pristiq
Pristiq is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8269040 | Derivatives of venlafaxine and methods of preparing and using the same |
05 Jul, 2027
(2 years from now)
| Active |
| US6673838 | Succinate salt of O-desmethyl-venlafaxine |
01 Mar, 2022
(3 years ago)
| Expired |
| US6673838 | Succinate salt of O-desmethyl-venlafaxine |
11 Feb, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pristiq's drug page
5. Rapamune
Rapamune is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5989591
(Pediatric)
| Rapamycin formulations for oral administration |
11 Sep, 2018
(6 years ago)
| Expired |
| US5989591 | Rapamycin formulations for oral administration |
11 Mar, 2018
(7 years ago)
| Expired |
| US5536729
(Pediatric)
| Rapamycin formulations for oral administration |
30 Mar, 2014
(11 years ago)
| Expired |
| US5100899
(Pediatric)
| Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
07 Jan, 2014
(11 years ago)
| Expired |
| US5536729 | Rapamycin formulations for oral administration |
30 Sep, 2013
(11 years ago)
| Expired |
| US5100899 | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
07 Jul, 2013
(11 years ago)
| Expired |
| US5403833
(Pediatric)
| Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
04 Oct, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rapamune's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Torisel
Torisel is protected by 14 patents, out of which 10 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8791097
(Pediatric)
| Anti-tumor activity of CCI-779 in papillary renal cell cancer |
10 Nov, 2032
(7 years from now)
| Active |
| US8791097 | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
10 May, 2032
(7 years from now)
| Active |
| US8026276
(Pediatric)
| Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
20 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8026276 | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
20 Jan, 2026
(8 months from now)
| Active |
| US8299116
(Pediatric)
| CCI-779 concentrate formulations |
25 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US8455539
(Pediatric)
| CCI-779 concentrate formulations |
25 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US8722700
(Pediatric)
| CCI-779 formulations for parenteral administration |
25 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US8299116 | CCI-779 concentrate formulations |
25 Jul, 2023
(1 year, 9 months ago)
| Expired |
| US8455539 | CCI-779 concentrate formulations |
25 Jul, 2023
(1 year, 9 months ago)
| Expired |
| US8722700 | CCI-779 formulations for parenteral administration |
25 Jul, 2023
(1 year, 9 months ago)
| Expired |
| USRE44768
(Pediatric)
| Rapamycin hydroxyesters |
15 Aug, 2019
(5 years ago)
| Expired |
| USRE44768 | Rapamycin hydroxyesters |
15 Feb, 2019
(6 years ago)
| Expired |
| US5362718
(Pediatric)
| Rapamycin hydroxyesters |
18 Oct, 2014
(10 years ago)
| Expired |
| US5362718 | Rapamycin hydroxyesters |
18 Apr, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Torisel's drug page
7. Tygacil
Tygacil is protected by 8 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8372995 | Crystalline solid forms of tigecycline and methods of preparing same |
08 Oct, 2030
(5 years from now)
| Active |
| US7879828 | Tigecycline compositions and methods of preparation |
05 Feb, 2029
(3 years from now)
| Active |
| US8975242 | Tigecycline compositions and methods of preparation |
24 Oct, 2028
(3 years from now)
| Active |
| US10588975 | Tigecycline compositions and methods of preparation |
13 Mar, 2026
(10 months from now)
| Active |
| US9254328 | Tigecycline compositions and methods of preparation |
13 Mar, 2026
(10 months from now)
| Active |
| US9694078 | Tigecycline compositions and methods of preparation |
13 Mar, 2026
(10 months from now)
| Active |
| USRE40183 | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
09 Apr, 2016
(9 years ago)
| Expired |
| USRE40086 | Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines |
25 Jun, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tygacil's drug page
8. Vfend
Vfend is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6632803 | Pharmaceutical formulations containing voriconazole |
02 Jun, 2018
(6 years ago)
| Expired |
| US5567817 | Triazole antifungal agents |
24 May, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vfend's drug page
9. Xalkori
Xalkori is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8217057 | Polymorphs of a c-MET/HGFR inhibitor |
06 Nov, 2029
(4 years from now)
| Active |
| US7858643 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
08 Oct, 2029
(4 years from now)
| Active |
| US7825137 | Method of treating abnormal cell growth |
12 May, 2027
(2 years from now)
| Active |
| US7230098 | Aminoheteroaryl compounds as protein kinase inhibitors |
26 Aug, 2025
(3 months from now)
| Active |
| US8785632 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
01 Mar, 2025
(2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xalkori's drug page
10. Xeljanz
Xeljanz is protected by 9 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE41783
(Pediatric)
| Pyrrolo[2,3-D]pyrimidine compounds |
08 Jun, 2026
(1 year, 29 days from now)
| Active |
| USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds |
08 Dec, 2025
(6 months from now)
| Active |
| US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
25 Mar, 2023
(2 years ago)
| Expired |
| US7301023 | Chiral salt resolution |
23 May, 2022
(2 years ago)
| Expired |
| US6956041 | Pyrrolo[2,3-d]pyrimidine compounds |
08 Dec, 2020
(4 years ago)
| Expired |
| US7091208 | Pyrrolo[2,3-D]pyrimidine compounds |
08 Dec, 2020
(4 years ago)
| Expired |
| US7265221 | Pyrrolo[2,3-d]pyrimidine compounds |
08 Dec, 2020
(4 years ago)
| Expired |
| US7301023 | Chiral salt resolution |
08 Dec, 2020
(4 years ago)
| Expired |
| US7842699 | Pyrrolo[2,3-D]pyrimidine compounds |
08 Dec, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xeljanz's drug page
11. Zmax
Zmax is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6984403 | Azithromycin dosage forms with reduced side effects |
14 Feb, 2024
(1 year, 2 months ago)
| Expired |
| US7887844 | Multiparticulate crystalline drug compositions having controlled release profiles |
14 Feb, 2024
(1 year, 2 months ago)
| Expired |
| US6268489 | Azithromycin dihydrate |
31 Jul, 2018
(6 years ago)
| Expired |
| US6068859 | Controlled-release dosage forms of Azithromycin |
30 May, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zmax's drug page